AOD-9604 (Anti-Obesity Drug 9604)

1. Overview

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino acid peptide corresponding to the C-terminal fragment (amino acids 177-to-191) of human growth hormone (hGH), with a tyrosine residue substituted at the N-terminus in place of the native phenylalanine. Its full sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, featuring a stabilizing intramolecular disulfide bridge between Cys-7 and Cys-14 that creates a constrained cyclic loop in the core of the molecule. The molecular weight is approximately 1,815 Da, with molecular formula C78H123N23O23S2 and CAS registry number 221231-10-3 [1][4][7].

The peptide was developed in the 1990s by Melbourne-based Metabolic Pharmaceuticals Limited, building on pioneering research by Professor Frank M. Ng and colleagues at Monash University, Australia. Their work through the early 1990s systematically mapped the functional domains of the 191-amino acid growth hormone molecule and identified that the C-terminal region -- specifically residues 177 through 191 -- contained the structural elements responsible for the lipolytic (fat-mobilizing) activity of growth hormone, independent of its growth-promoting or diabetogenic effects [1][2][3].

The earlier precursor peptide was designated AOD-9401, corresponding to the unmodified hGH 177-to-191 fragment without the N-terminal tyrosine. AOD-9604 incorporated the phenylalanine-to-tyrosine substitution at position 1 to improve peptide stability and oral bioavailability [5][10]. This single amino acid modification is the defining structural difference between AOD-9604 and the unmodified hGH Fragment 176-to-191 sold in the research peptide market.

AOD-9604 advanced through six human clinical trials involving over 890 participants between 2001 and 2006. However, the pivotal 24-week Phase IIb trial (the OPTIONS Study, enrolling 536 obese adults) failed to demonstrate statistically significant weight loss versus placebo, and development for obesity was discontinued by Metabolic Pharmaceuticals in early 2007 [12][14]. The company subsequently rebranded as Calzada (2009), then PolyNovo Biomaterials (2014), before selling all AOD-9604 intellectual property rights in 2015. More recently, AOD-9604 has been investigated for osteoarthritis and cartilage repair [16], and it has gained a self-affirmed GRAS (Generally Recognized As Safe) determination as a food ingredient [15] while becoming a focus of regulatory controversy surrounding compounding pharmacy access in the United States [20].

Molecular Weight

~1,815.10 Da

Sequence

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa, disulfide Cys7-Cys14)

Chemical Formula

C78H123N23O23S2

CAS Number

221231-10-3

Half-life

Not well characterized in humans; rapidly degraded in serum

Routes Studied

Oral, subcutaneous, intravenous, intra-articular, intraperitoneal (animal)

FDA Status

Not approved as drug; GRAS self-affirmed as food ingredient (2014); rejected by PCAC for compounding (Dec 2024)

WADA Status

Prohibited at all times (S0: Non-Approved Substances)

2. Molecular Structure

AOD-9604 is a 16-residue peptide with the one-letter amino acid sequence YLRIVQCRSVEGSCGF. The three-dimensional solution structure was determined by Ogru et al. (2000) using two-dimensional proton NMR spectroscopy [7]. The two cysteine residues at positions 7 and 14 form an intramolecular disulfide bond, creating a constrained cyclic region spanning residues 7 through 14. Within this cyclic core, the peptide adopts type I beta-turns at residues Ser8-Val9-Glu10-Gly11 and Ser12-Cys13-Gly14-Phe15, each preceded by loop-like structures [7].

The N-terminal tyrosine distinguishes AOD-9604 from both the native hGH C-terminal sequence (which has phenylalanine at position 177) and the unmodified hGH Fragment 176-to-191 research peptide. This substitution improves metabolic stability and was shown in comparative preclinical studies to enhance lipolytic potency per unit dose relative to the unmodified fragment [5][10]. Importantly, every human clinical trial conducted on this fragment class -- all six studies enrolling over 890 participants -- used the AOD-9604 (tyrosine-modified) form specifically. The unmodified hGH Fragment 176-to-191 has never been tested in humans.

The peptide contains only a partial overlap with one of the two GH receptor binding sites and completely lacks the other, meaning it physically cannot activate the GH receptor or stimulate IGF-1 production [6][8].

3. Mechanism of Action

AOD-9604 stimulates lipolysis (hydrolysis of stored triglycerides into free fatty acids and glycerol) and inhibits lipogenesis (de novo fat synthesis) in adipose tissue. The primary mechanism operates through the beta-3 adrenergic receptor (beta3-AR) pathway rather than through GH receptor signaling [9]:

1. AOD-9604 upregulates beta3-AR messenger RNA expression on adipocyte cell surfaces, raising repressed levels in obese animals to levels comparable with those in lean controls [9].
2. Enhanced beta3-AR signaling stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels.
3. Elevated cAMP activates protein kinase A (PKA).
4. PKA phosphorylates and activates hormone-sensitive lipase (HSL), which hydrolyzes stored triglycerides [5].
5. Released free fatty acids enter mitochondrial beta-oxidation pathways for energy production.

Additionally, AOD-9604 inhibits acetyl-CoA carboxylase, the rate-limiting enzyme in de novo lipogenesis, reducing the conversion of carbohydrate substrates into new fat stores [5].

Beta3-AR Knockout Evidence

The critical role of beta3-AR signaling was demonstrated definitively by Heffernan et al. (2001) using beta3-AR knockout mice. Chronic AOD-9604 treatment produced no changes in body weight or lipolysis in these knockout animals, whereas identical treatment significantly reduced body weight in wild-type obese mice [9]. Interestingly, acute AOD-9604 exposure still enhanced energy expenditure in knockout animals, suggesting the involvement of secondary pathways for acute metabolic effects, while confirming that the chronic anti-obesity activity depends entirely on beta3-AR upregulation [9].

Dissociation from Growth Hormone Actions

Unlike full-length growth hormone, AOD-9604 does not bind to the GH receptor (GHR), does not stimulate IGF-1 production, does not promote linear growth or organ growth, and does not produce diabetogenic effects [4][6][8]. This dissociation was confirmed through multiple lines of evidence. Euglycemic clamp studies in obese Zucker rats showed no adverse effect on insulin sensitivity after chronic AOD-9604 treatment, in contrast to intact hGH which significantly impaired insulin action [4]. Heffernan et al. (2001) demonstrated that AOD-9604 did not compete for GH receptor binding and did not induce cell proliferation, confirming a mechanism entirely independent of the classical GH-IGF-1 axis [6][8]. Across all six human clinical trials, AOD-9604 produced no changes in serum IGF-1 levels, no glucose intolerance, and no insulin resistance [14].

4. Development History

Discovery at Monash University (1990s)

The origins of AOD-9604 trace to work by Professor Frank M. Ng at Monash University in Melbourne, Australia, who had studied growth hormone biology for decades. In 1993, Wu and Ng published the foundational finding that the synthetic C-terminal peptide hGH(177-to-191) possessed antilipogenic activity identical to intact growth hormone when tested in isolated adipocytes [1]. Natera, Jiang, and Ng (1994) confirmed in vivo activity, demonstrating that chronic treatment with the synthetic fragment reduced cumulative body weight gain and adipose tissue mass in ob/ob mice [2].

Creation of AOD-9604 and Preclinical Development

By the late 1990s, the Monash group had created AOD-9604 by adding an N-terminal tyrosine to the hGH(177-to-191) fragment to improve stability. Ng et al. (2000) published the landmark metabolic study demonstrating that oral AOD-9604 at 500 mcg/kg/day reduced body weight gain by over 50 percent in obese Zucker rats (15.8 plus-or-minus 0.6 g versus 35.6 plus-or-minus 0.8 g in controls) over 19 days, without impairing insulin sensitivity [4]. Concurrent studies by Ng et al. characterized the cellular mechanism, showing stimulation of hormone-sensitive lipase and inhibition of acetyl-CoA carboxylase [5], while Heffernan et al. demonstrated oral bioavailability and confirmed that the fragment did not compete for GH receptor binding [6].

Ogru et al. (2000) solved the three-dimensional solution structure by NMR and confirmed that AOD-9604 stimulated lipolysis and inhibited lipogenesis in rodent, porcine, and human adipose tissues in vitro, supporting its candidacy as a potential therapeutic for obesity [7].

Metabolic Pharmaceuticals and Clinical Trials (2001-2007)

Metabolic Pharmaceuticals Limited, an Australian biotechnology company, licensed the technology from Monash University and advanced AOD-9604 into clinical development. The company conducted six controlled clinical trials between 2001 and 2006 [14]:

Phase I studies evaluated single ascending oral doses (9, 27, and 54 mg) and established basic pharmacokinetic and safety parameters. The highest dose (54 mg) was associated with mild gastrointestinal discomfort but no serious adverse events [14].

Phase IIa trial (METAOD005, approximately 2004): This 12-week randomized, double-blind, placebo-controlled study enrolled approximately 300 obese adults at five Australian trial sites. Participants received oral AOD-9604 at doses of 1, 5, 10, 20, or 30 mg daily, or placebo. The 1 mg dose group showed the greatest weight loss, averaging 2.8 kg over 12 weeks compared to 0.8 kg in the placebo group -- more than triple the placebo response. The rate of weight loss was maintained throughout the treatment period, and small improvements in cholesterol profiles and glucose tolerance were observed. Notably, the dose-response was non-linear, with the lowest dose producing the largest effect [12].

Phase IIb OPTIONS Study (approximately 2006-2007): This pivotal 24-week study enrolled 536 obese adults (BMI 30 to 45) across multiple centers. Based on the Phase IIa dose-response data suggesting efficacy at lower doses, participants received oral AOD-9604 at 0.25, 0.5, or 1 mg daily, or placebo. The trial failed to meet its primary endpoint of statistically significant weight loss versus placebo. While treated groups showed trends toward greater weight loss (approximately 1 to 2 kg vs. 0.8 kg for placebo), the results were not robust enough to support continued development. Metabolic Pharmaceuticals announced discontinuation of the obesity program in early 2007 [14].

Post-Discontinuation (2007-Present)

Metabolic Pharmaceuticals rebranded as Calzada Limited in 2009, which subsequently became PolyNovo Biomaterials in 2014. In 2015, PolyNovo sold all intellectual property rights for AOD-9604. The compound's development focus shifted toward cartilage repair and joint health applications, and the safety data were compiled to support regulatory designations as a nutraceutical ingredient [15][16].

5. Researched Applications

Fat Loss and Obesity

Evidence level: Preliminary (Phase II trials did not meet primary endpoints)

The primary application explored for AOD-9604 was anti-obesity therapy. Animal studies consistently demonstrated reduced body weight gain (over 50 percent reduction vs. controls in obese Zucker rats over 19 days) [4], decreased adipose tissue mass and adipocyte cell size (from 110 to 80 micrometers) [5], increased in vivo fat oxidation and plasma glycerol levels [6][8], no effect on food intake or lean body mass, and no diabetogenic effects [4][6].

However, human clinical trials showed only modest results. The Phase IIa trial (approximately 300 obese adults, 12 weeks) showed the 1 mg dose group lost 2.8 kg vs. 0.8 kg for placebo, but with a non-linear dose-response that complicated dose selection [12]. The pivotal Phase IIb OPTIONS Study (536 obese adults, 24 weeks) failed to meet its primary endpoint of statistically significant weight loss versus placebo [14]. The disconnect between robust animal efficacy and modest human results may relate to species differences in beta3-AR expression and distribution in adipose tissue, oral bioavailability limitations in humans, or insufficient dosing duration and dose optimization in the clinical program.

Cartilage Repair and Osteoarthritis

Evidence level: Preclinical

Kwon and Park (2015) demonstrated in a rabbit collagenase-induced knee osteoarthritis model (n=32 rabbits) that intra-articular AOD-9604 injections enhanced cartilage regeneration [16]. Notably, the combination of AOD-9604 plus hyaluronic acid (HA) was superior to either agent alone. Histological scoring showed significantly better outcomes in the combination group, and the lameness recovery period was significantly shorter in animals receiving both agents compared to AOD-9604 alone, HA alone, or untreated controls [16].

Preclinical in vitro studies have shown that AOD-9604 stimulates proteoglycan synthesis in chondrocyte cultures, suggesting direct anabolic effects on cartilage extracellular matrix. This chondroprotective activity represents a potential second therapeutic application distinct from the original obesity indication, though no human clinical trials for cartilage repair or osteoarthritis have been published to date.

Cancer Research

Evidence level: In vitro only

Habibullah et al. (2022) found that the hGH fragment 176-to-191 peptide substantially enhanced the cytotoxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells in vitro [19]. This is an early exploratory finding with no in vivo follow-up, and the clinical relevance remains entirely speculative.

6. Clinical Evidence Summary

7. Dosing in Research

The following table summarizes doses used in published research studies. These are not therapeutic recommendations. AOD-9604 is not approved for human therapeutic use by any regulatory authority.

8. Safety and Side Effects

AOD-9604 demonstrated an excellent safety profile across all six human clinical trials (893 participants total) [14]. Stier, Vos, and Kenley (2013) conducted a comprehensive review of all available safety data and concluded that the safety and tolerability profile was "indistinguishable from placebo" [14]. Key safety findings included: adverse event rates comparable between AOD-9604 and placebo groups at all doses tested; no withdrawals or serious adverse events related to AOD-9604 in any study; no clinically significant changes in IGF-1 levels, blood glucose, HbA1c, or insulin levels; no effects on liver function, kidney function, hematological parameters, or cardiovascular parameters; and no anti-AOD9604 antibodies detected in any of the patients assessed [14].

In preclinical toxicology testing, AOD-9604 was found to be generally safe after chronic oral administration in both rats and cynomolgus monkeys, with no evidence of genotoxic activity in Ames tests, chromosomal aberration assays, or bone marrow micronucleus assays [15]. Unlike intact hGH, AOD-9604 does not cause insulin resistance, hyperglycemia, or stimulate cellular proliferation in animal models [4][5][6].

Cox et al. (2015) identified six potential metabolites of AOD-9604 after incubation in serum and urine. The metabolite CRSVEGSCG (a central loop fragment) was found to be significantly more stable than the parent compound or other metabolites, representing the most reliable target for anti-doping urine testing [17].

Limitations: Long-term safety data beyond 24 weeks of continuous use in humans are limited to the Phase IIb trial population. No published safety data exist for subcutaneous or intra-articular administration in humans. The FDA's Pharmacy Compounding Advisory Committee cited potential immunogenicity risk and peptide-related impurities as concerns when reviewing AOD-9604 for compounding use in December 2024 [20].

9. AOD-9604 vs. hGH Fragment 176-191

Both peptides share the same core amino acid sequence derived from the C-terminal region (residues 177-to-191) of human growth hormone. The key differences are:

Structural distinction: AOD-9604 has a tyrosine at the N-terminus where hGH Fragment 176-to-191 retains the native leucine (or in some formulations, phenylalanine). This single amino acid modification alters stability and potency.

Clinical evidence: All six human clinical trials (over 890 participants) were conducted exclusively with AOD-9604. The unmodified hGH Fragment 176-to-191 has never been studied in humans. Therefore, any human safety data -- including the favorable "indistinguishable from placebo" safety profile -- applies only to AOD-9604 [14].

Stability: The tyrosine substitution improves resistance to proteolytic degradation, extending the peptide's functional half-life. Comparative preclinical data suggest AOD-9604 demonstrates stronger lipolytic activity per unit dose than the unmodified fragment [5][10].

Shared mechanism: Both peptides stimulate lipolysis and inhibit lipogenesis through beta3-AR upregulation without binding to the GH receptor. Neither produces diabetogenic effects, IGF-1 elevation, or growth-promoting activity [6][8][9].

10. Regulatory Status

United States (FDA)

AOD-9604 is not approved as a pharmaceutical drug for any indication. In 2014, a self-affirmed GRAS (Generally Recognized As Safe) determination was made by a qualified expert panel for use of AOD-9604 as a food ingredient at specified levels [15]. However, this GRAS determination relates only to safety as a nutraceutical ingredient, not to therapeutic efficacy claims. In September 2023, the FDA placed AOD-9604 on Category 2 of the interim 503A bulks list (substances raising significant safety concerns for compounding). The nomination was withdrawn in September 2024, and at the December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting, the committee voted against including AOD-9604 on the 503A Bulks List, citing immunogenicity risk, peptide impurity concerns, and limited long-term safety data [20]. As of early 2026, AOD-9604 cannot be legally compounded by 503A pharmacies in the United States.

Australia (TGA)

The Therapeutic Goods Administration has included AOD-9604 as a permitted ingredient in listed complementary medicines, particularly for cartilage and joint health applications. This classification followed the shift in development focus from obesity to musculoskeletal indications after 2007. Development as a prescription pharmaceutical for obesity was discontinued by Metabolic Pharmaceuticals. The TGA classification is distinct from drug approval and pertains to its use as a complementary medicine ingredient.

WADA (World Anti-Doping Agency)

AOD-9604 is prohibited at all times under the WADA Prohibited List. Initially, confusion arose about its classification. WADA clarified in April 2013 that AOD-9604 had been considered a prohibited substance under Category S0 (Non-Approved Substances -- any pharmacological substance not addressed by subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use) since at least 2011 [18]. This clarification came during the investigation into the Essendon Football Club supplements scandal in Australian rules football, where AOD-9604 was among the substances administered to players during a controversial supplements injection program in 2011-2012. Validated urine detection methods exist with a limit of detection of 50 pg/mL [17]. The most stable urinary metabolite for detection is the central fragment CRSVEGSCG [17].

European Union (EMA)

Not approved for any indication. No marketing authorization has been sought or granted.

11. The Essendon Supplements Scandal

AOD-9604 gained worldwide notoriety through the Essendon Football Club supplements saga, one of the largest doping scandals in Australian sports history. During 2011-2012, the Essendon Bombers of the Australian Football League (AFL) operated a supplements injection program overseen by biochemist Stephen Dank. AOD-9604 was among the substances administered to players, as acknowledged on signed consent forms and in public statements.

The Australian Sports Anti-Doping Authority (ASADA) began investigating in February 2013. Metabolic Pharmaceuticals' successor company denied involvement, stating no human trials had been conducted since 2007. WADA clarified in April 2013 that AOD-9604 was prohibited under S0, though ASADA ultimately decided not to pursue AOD-9604-specific charges for use before that clarification date. The case ultimately centered on another peptide, Thymosin Beta-4, with 34 past and present Essendon players receiving two-year bans in January 2016. The scandal prompted WADA to explicitly clarify the prohibited status of emerging peptides and highlighted the difficulty of policing substances that lack formal marketing approval anywhere in the world.

12. Pharmacokinetics

What Is Known

The pharmacokinetics of AOD-9604 in humans are incompletely characterized in published literature. Unlike many peptide therapeutics with detailed PK profiles, AOD-9604's clinical development was discontinued before comprehensive pharmacokinetic studies were published. Key known parameters include:

Oral bioavailability: Confirmed in preclinical studies. Heffernan et al. (2000) demonstrated oral activity in ob/ob mice, with oral administration producing significant reductions in body weight and increases in fat oxidation [6]. The peptidomimetic structure (16 amino acids with a stabilizing disulfide bridge) provides modest resistance to gastrointestinal proteolysis, and the N-terminal tyrosine substitution further improves metabolic stability compared to the unmodified hGH Fragment 176-191 [5][10]. All six human clinical trials used oral administration, confirming sufficient oral bioavailability for biological activity in humans [14].

Serum stability: AOD-9604 is rapidly degraded in human serum. Cox et al. (2015) identified six metabolites following incubation of AOD-9604 in serum and urine, indicating that proteolytic degradation proceeds through multiple cleavage sites [17]. The central loop fragment CRSVEGSCG (encompassing the disulfide-constrained cyclic region) was the most stable metabolite, persisting significantly longer than the intact parent peptide or other degradation products [17].

Estimated half-life: The plasma half-life of AOD-9604 has not been precisely reported in published human PK studies. Based on its 16-amino acid peptide structure with a single disulfide bond and rapid serum degradation observed in vitro, the circulating half-life is likely in the range of minutes to low single-digit hours -- consistent with other small linear/cyclic peptides of similar size that lack albumin-binding or PEGylation modifications. The Phase IIa dose-response data, showing efficacy with once-daily oral dosing, suggest that the pharmacodynamic effects persist beyond the pharmacokinetic elimination window, potentially through downstream signaling cascades (beta3-AR upregulation, HSL activation) that outlast the peptide's presence in plasma [4][9].

Metabolic pathway: AOD-9604 does not interact with CYP450 enzymes and is cleared through proteolytic degradation rather than hepatic metabolism. This eliminates CYP-mediated drug-drug interaction concerns [14][15].

Subcutaneous and Intra-Articular Routes

No published human pharmacokinetic data exist for subcutaneous or intra-articular AOD-9604 administration. In the rabbit osteoarthritis model, intra-articular AOD-9604 at 0.25 mg weekly demonstrated local biological activity (cartilage regeneration), suggesting adequate joint retention for biological effect [16]. Subcutaneous pharmacokinetics would be expected to provide higher systemic bioavailability than oral administration, but no clinical PK data are available.

Anti-Doping Detection

Cox et al. (2015) developed a validated urine detection method for AOD-9604 with a limit of detection of 50 pg/mL [17]. The most reliable urinary marker for anti-doping testing is the CRSVEGSCG metabolite fragment, which is more stable than the parent compound in biological matrices. The detection window depends on dose and route, but urinary metabolites are detectable for at least several hours following administration [17][21].

13. Dose-Response Relationships

Fat Loss Dose-Response (Animal Data)

Preclinical dose-response data are robust and consistent across multiple obesity models:

Obese Zucker rats (Ng et al. 2000): 500 mcg/kg/day intraperitoneally for 19 days produced greater than 50% reduction in cumulative body weight gain (15.8 +/- 0.6 g vs. 35.6 +/- 0.8 g in controls, P value significant). No adverse effects on insulin sensitivity by euglycemic clamp [4].

ob/ob mice (Heffernan et al. 2001): Chronic IP treatment reduced body weight and fat mass while increasing in vivo fat oxidation. Critically, AOD-9604 did not produce the hyperglycemia or insulin resistance seen with equimolar doses of intact hGH, confirming the dissociation of lipolytic from diabetogenic effects [8].

ob/ob mice (Heffernan et al. 2000, oral): Oral dosing for 14 days confirmed oral bioavailability and demonstrated increased fat oxidation and reduced body weight without GH receptor competition [6].

Fat Loss Dose-Response (Human Data)

Human dose-response data show an unusual non-linear pattern that complicated clinical development:

Phase IIa (12 weeks, approximately 300 obese adults):

| Dose (mg daily, oral) | Weight Loss (kg) | vs. Placebo | Notes | |---|---|---|---| | Placebo | -0.8 kg | -- | Modest placebo response | | 1 mg | -2.8 kg | +2.0 kg | Best response; 3.5x placebo | | 5 mg | Less effective than 1 mg | -- | Non-linear dose-response | | 10 mg | Less effective than 1 mg | -- | Paradoxical reduction | | 20 mg | Less effective than 1 mg | -- | Inverted dose-response | | 30 mg | Less effective than 1 mg | -- | Highest dose least effective |

The inverted dose-response curve -- with the lowest dose (1 mg) producing the greatest weight loss -- was unexpected and created significant challenges for dose selection in the Phase IIb trial [12]. Possible explanations include receptor desensitization or downregulation at higher doses, saturation of the oral absorption pathway, or beta3-AR tachyphylaxis with greater receptor stimulation.

Phase IIb OPTIONS Study (24 weeks, 536 obese adults):

Based on the Phase IIa non-linear dose-response suggesting efficacy at lower doses, the Phase IIb trial tested doses of 0.25, 0.5, and 1 mg daily. All three doses showed trends toward greater weight loss than placebo (approximately 1-2 kg vs. 0.8 kg), but none reached statistical significance, and the primary endpoint was not met [14].

The disconnect between robust animal efficacy (greater than 50% reduction in weight gain) and modest human results likely reflects:

• Species differences in beta3-AR expression: Beta3-AR is abundantly expressed in rodent brown and white adipose tissue but has much lower expression in human adipose tissue, particularly in visceral fat depots
• Oral bioavailability limitations: Insufficient systemic exposure via the oral route in humans
• Dose selection challenges: The non-linear Phase IIa dose-response may have led to suboptimal doses in Phase IIb

14. Comparative Effectiveness

AOD-9604 vs. hGH Fragment 176-191

These two peptides are frequently confused in the research peptide market. The critical distinctions are:

| Parameter | AOD-9604 | hGH Fragment 176-191 | |---|---|---| | N-terminal residue | Tyrosine (substituted) | Leucine or Phenylalanine (native) | | Human clinical data | 6 trials, 893 participants | None (never tested in humans) | | Safety database | "Indistinguishable from placebo" [14] | No human safety data exist | | Proteolytic stability | Improved (Tyr substitution) | Lower (native sequence) | | Lipolytic potency (preclinical) | Enhanced per unit dose [5][10] | Reference | | Mechanism | Identical (beta3-AR upregulation) | Identical | | GH receptor binding | None (cannot activate GHR) | None | | IGF-1 stimulation | None | None |

Critical point: All published human safety and efficacy data apply exclusively to AOD-9604. The unmodified hGH Fragment 176-191 sold in research peptide markets has no human clinical evidence.

AOD-9604 vs. Full-Length Human Growth Hormone (hGH)

| Parameter | AOD-9604 | Full-Length hGH (Somatropin) | |---|---|---| | Size | 16 amino acids (1,815 Da) | 191 amino acids (22,124 Da) | | GH receptor binding | No | Yes (primary mechanism) | | IGF-1 stimulation | No | Yes (significant) | | Lipolytic effect | Yes (beta3-AR pathway) | Yes (both GHR-dependent and beta3-AR) | | Diabetogenic effects | None [4] | Yes (insulin resistance, hyperglycemia) | | Growth-promoting effects | None | Yes (linear growth, organ growth) | | Fluid retention | None | Common (GH-mediated) | | Carpal tunnel syndrome | None | Occurs with chronic GH use | | Tumor promotion concern | None demonstrated | Theoretical risk (IGF-1 elevation) | | Route | Oral (confirmed) or SC | SC or IM injection only | | Regulatory status | Not approved as drug | FDA-approved (multiple indications) | | Weight loss evidence | Phase IIb failed [14] | Modest fat reduction in GH-deficient adults |

The key advantage of AOD-9604 over hGH is the complete dissociation of lipolytic activity from diabetogenic, growth-promoting, and other GH receptor-mediated effects. This was the original therapeutic rationale: harnessing the fat-reducing domain of GH without the adverse metabolic consequences of full GH receptor activation [1][4][8].

AOD-9604 vs. Modern Anti-Obesity Therapies

To contextualize AOD-9604's clinical failure, comparison with currently approved obesity pharmacotherapies is instructive:

| Agent | Mechanism | Pivotal Trial Weight Loss | Approval Status | |---|---|---|---| | AOD-9604 | Beta3-AR upregulation (hGH fragment) | Failed primary endpoint (~1-2 kg, NS) | Not approved; development discontinued | | Semaglutide 2.4 mg (Wegovy) | GLP-1R agonist | ~15-17% (~15-17 kg) (STEP program) | FDA-approved (2021) | | Tirzepatide (Zepbound) | GIP/GLP-1R dual agonist | ~21-26% (SURMOUNT program) | FDA-approved (2023) | | Orlistat (Xenical/Alli) | Lipase inhibitor | ~3-4% (~3-4 kg) above placebo | FDA-approved (1999) | | Phentermine/topiramate (Qsymia) | Sympathomimetic + anticonvulsant | ~8-10% (EQUIP/CONQUER) | FDA-approved (2012) |

AOD-9604's approximately 1-2 kg weight loss above placebo, even at its best (Phase IIa, 1 mg dose), would place it well below the efficacy threshold of any currently approved anti-obesity medication. The GLP-1 and GIP/GLP-1 receptor agonists represent a different order of magnitude of weight loss efficacy.

15. Enhanced Safety Profile

Human Safety Database

AOD-9604 possesses an unusually comprehensive safety database for a failed drug candidate, with 893 participants across six controlled clinical trials [14]. The safety profile is summarized as "indistinguishable from placebo" based on a systematic review by Stier, Vos, and Kenley (2013):

| Safety Parameter | AOD-9604 (All Doses) | Placebo | Significance | |---|---|---|---| | Adverse event incidence | Comparable | Reference | No difference | | Serious adverse events | None drug-related | Reference | No difference | | Withdrawals due to AEs | None drug-related | Reference | No difference | | IGF-1 levels | No change | No change | Confirms no GH axis activation | | Fasting glucose | No change | No change | No diabetogenic effect | | HbA1c | No change | No change | No chronic glucose effect | | Insulin levels | No change | No change | No insulin resistance | | Liver function | No change | No change | No hepatotoxicity | | Renal function | No change | No change | No nephrotoxicity | | Hematology | No change | No change | No blood dyscrasias | | Cardiovascular parameters | No change | No change | No cardiac effects | | Anti-AOD9604 antibodies | Not detected | N/A | No immunogenicity (oral route) |

Preclinical Toxicology

Comprehensive preclinical toxicology testing found [15]:

• Genotoxicity: Negative in Ames test, chromosomal aberration assay, and bone marrow micronucleus assay
• Chronic oral toxicity (rats): No adverse findings after chronic dosing
• Chronic oral toxicity (cynomolgus monkeys): No adverse findings after chronic dosing
• Reproductive toxicity: Not extensively reported
• Carcinogenicity: No formal 2-year carcinogenicity studies published

FDA PCAC Concerns (December 2024)

Despite the favorable clinical safety database, the FDA Pharmacy Compounding Advisory Committee raised specific concerns when reviewing AOD-9604 for inclusion on the 503A Bulks List [20]:

1. Immunogenicity risk: While no anti-AOD9604 antibodies were detected in oral administration trials, the committee noted that subcutaneous injection (the route commonly used by compounding pharmacies) could present a different immunogenicity profile, as parenteral exposure to peptides is more likely to generate immune responses than oral exposure.

2. Peptide impurity concerns: The committee raised questions about the consistency of peptide synthesis quality from compounding sources versus the GMP-manufactured material used in clinical trials. Aggregation, misfolding, or oxidation products could introduce immunogenic epitopes not present in the clinical trial material.

3. Limited long-term safety data: The longest human exposure was 24 weeks (Phase IIb). No data exist for chronic use beyond 6 months.

4. Route extrapolation: All human safety data are from oral administration. No published human safety data exist for subcutaneous, intra-articular, or intravenous routes, which are being used by compounding pharmacies and clinics.

The PCAC voted against including AOD-9604 on the 503A Bulks List, effectively prohibiting its compounding by 503A pharmacies in the United States as of the decision date [20].

February 2026 Reclassification: On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that AOD-9604 would be among approximately 14 peptides moved from FDA Category 2 back to Category 1, restoring legal access through licensed compounding pharmacies with a physician's prescription. This reversal overrides the December 2024 PCAC recommendation. The reclassification does not constitute FDA approval; compounded medications remain non-FDA-approved formulations. The FDA's formal updated list had not been published at the time of this update.

Key Safety Limitations

• No human safety data beyond 24 weeks of continuous use
• No human safety data for subcutaneous or intra-articular administration
• No formal drug interaction studies published
• No safety data in pregnant or lactating women
• No pediatric safety data
• The favorable safety profile applies exclusively to AOD-9604 (Tyr-modified) -- not to the unmodified hGH Fragment 176-191

16. Related Peptides

See also: HGH Fragment 176-191, Human Growth Hormone (hGH), Ipamorelin, CJC-1295, Tesamorelin, Semaglutide

17. References

1. [1] Wu Z, Ng FM. (1993). Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int. PubMed
2. [2] Natera SH, Jiang WJ, Ng FM. (1994). Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochem Mol Biol Int. PubMed
3. [3] Wu Z, Ng FM. (1994). Effect of an antilipogenic fragment of human growth hormone on glucose transport in rat adipocytes. Biochem Mol Biol Int. PubMed
4. [4] Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. DOI PubMed
5. [5] Ng FM, Jiang WJ, Gianello R, Pitt S, Rae T. (2000). Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. Journal of Molecular Endocrinology. PubMed
6. [6] Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. (2000). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology - Endocrinology and Metabolism. PubMed
7. [7] Ogru E, Wilson JC, Heffernan M, Jiang WJ, Chalmers DK, Libinaki R, Ng F. (2000). The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone. Journal of Peptide Research. DOI PubMed
8. [8] Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. DOI PubMed
9. [9] Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. DOI PubMed
10. [10] Jiang WJ, Gianello R, Heffernan M, Ogru E, Libinaki R, Ng FM. (2001). Development of a Human Growth Hormone Peptide Analogue AOD9604 into an Anti-Obesity Drug. In: Bentham Science (eds) Growth Hormone and Related Proteins.
11. [11] Wilding J. (2004). AOD-9604 (Metabolic Pharmaceuticals). Current Opinion in Investigational Drugs. PubMed
12. [12] Thompson G, Kenley D, Guo Y, et al. (2004). The effect of AOD9604 on weight loss in obese adults: results of a randomized, double-blind, placebo-controlled, multicenter study. Presented at International Congress on Obesity.
13. [13] Ioannides-Demos LL, Proietto J, McNeil JJ. (2005). Pharmacotherapy for obesity. Drugs. PubMed
14. [14] Stier H, Vos E, Kenley D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism.
15. [15] More MI, Kenley D. (2014). Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism. DOI
16. [16] Kwon DR, Park GY. (2015). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical and Laboratory Science. PubMed
17. [17] Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. (2015). Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. DOI PubMed
18. [18] WADA. (2013). WADA statement on substance AOD-9604. World Anti-Doping Agency Official Statement.
19. [19] Habibullah MM, Mohan S, Syed NK, et al. (2022). Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Design, Development and Therapy. DOI PubMed
20. [20] FDA Pharmacy Compounding Advisory Committee. (2024). PCAC Meeting - AOD-9604 Acetate Review. FDA PCAC Proceedings, December 4, 2024.
21. [21] Thomas A, Thevis M. (2012). Determination of small peptides in doping control urine samples by nano-LC/benchtop quadrupole orbitrap tandem mass spectrometry. Analytical Chemistry.